VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ETON
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ETONEton Pharmaceuticals, Inc.
$61.99$1.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksETONCash Flow

Eton Pharmaceuticals, Inc. (ETON) Cash Flow Statement

9Y historyFree accessUpdated daily

Operating cash flow swung from -$11.6M in 2025Q4 to $35.2M in 2026Q3, with the cash-to-net-income ratio fluctuating sharply, suggesting cash conversion depends heavily on working capital timing.

Income StatementBalance SheetCash FlowRatios

ETON Cash Flow Statement

Annual statement

ETON Cash Flow Statement

Eton Pharmaceuticals, Inc. (ETON) cash flow statement — 9-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Cash from Operations38.35M10.52M969K6.82M4.82M-4.72M-22.35M-18.03M-8.14M-4.72M
Operating CF Margin %-13.16%2.48%21.54%22.69%-21.62%-57297.44%-1879.67%--
Operating CF Growth %-971.43%986.07%-85.78%41.36%202.12%78.87%-23.97%-121.31%-72.64%-
Net Income49.86M-4.6M-3.82M-936K-9.02M-1.96M-27.97M-18.32M-12.74M-7.16M
Depreciation & Amortization4.98M4.04M1.15M901K1.77M462K651K447K63K13K
Stock-Based Compensation7.42M5.51M3.17M3.14M4.22M3.38M2.58M1.89M1.85M2.64M
Deferred Taxes-12.89M0000-546K0000
Other Non-Cash Items5.61M6.43M1.18M184K189K148K1.39M16K2.58M1.29M
Working Capital Changes-16.63M-859K-698K3.53M7.66M-6.21M1.01M-2.06M99K623K
Change in Receivables-13.41M-6.4M-3.12M-1.56M3.62M-5.42M425K-473K00
Change in Inventory2.8M-5.88M-1.31M-354K-7K692K-862K-380K00
Change in Payables2.24M6.81M2.32M53K-8K-570K1.77M-377K413K539K
Cash from Investing-18.36M-333K-40.01M-775K-2.79M-2.56M-50K-1.85M-236K-130K
Capital Expenditures-15.13M-333K-26K-775K-38K-3.26M-50K-1.1M-236K-130K
CapEx % of Revenue10.73%0.42%0.07%2.45%0.18%14.93%128.21%114.29%--
Acquisitions00-30M00700K0000
Investments----------
Other Investing-3.23M0-9.99M0-2.75M00-750K00
Cash from Financing-1.49M815K32.59M-957K-134K391K31.63M5.2M21.96M18M
Debt Issued (Net)-8M024.15M-1.16M-385K-150K2.48M4.75M00
Equity Issued (Net)6.51M598K8.19M00541K28.78M022.8M0
Dividends Paid00000000-1.05M0
Share Repurchases0000000000
Other Financing0217K248K198K251K0367K453K205K18M
Net Change in Cash18.51M11.01M-6.45M5.08M1.9M-6.89M9.23M-14.67M13.58M13.16M
Free Cash Flow38.22M10.19M943K6.04M2.03M-7.98M-22.4M-19.87M-8.38M-4.85M
FCF Margin %27.09%12.75%2.42%19.09%9.57%-36.55%-57425.64%-2072.16%--
FCF Growth %81.87%980.7%-84.39%197.1%125.48%64.37%-12.7%-137.11%-72.88%-
FCF per Share1.150.380.040.240.08-0.32-1.07-1.12-1.31-0.28
FCF Conversion (FCF/Net Income)0.77x-2.29x-0.25x-7.28x-0.53x2.41x0.80x0.98x0.64x0.66x
Interest Paid3.33M0665K842K730K00000
Taxes Paid107K082K247K000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile quarterly cash conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Quality Lags Cash Generation

According to reported quarterly figures, ETON's operating cash flow swung from negative $11.6M in 2025Q4 to positive $35.2M in 2026Q3, with the cash-to-net-income ratio fluctuating sharply rather than tracking earnings steadily.

The operating cash flow to net income ratio ranges from roughly 0.6 to over 4.7 across recent quarters, which suggests that reported earnings are not translating into cash in a consistent manner. The 2026Q3 ratio of 1.00 is largely a function of a $35.2M operating cash inflow matching net income, but the preceding quarters show large working capital swings that appear to drive the timing gap. Investors should monitor whether conversion normalizes once the current quarter's working capital effects reverse, as the current cash picture may not be representative of recurring operations.

Free Cash Flow Turns Sharply Positive

As reported in financial statements, ETON's free cash flow reached $35.2M in 2026Q3 on a 60.8% margin, a marked improvement from the negative $11.6M recorded in 2025Q4.

Capex has been minimal relative to revenue in most recent quarters, so free cash flow closely tracks operating cash flow, making working capital the dominant driver of the trajectory. The 2026Q1 capex/revenue spike of 62.1% appears to be an isolated investment outlay rather than a recurring pattern. The sustainability of the 60.8% FCF margin warrants caution, since it likely reflects a favorable working capital release instead of structurally higher cash earnings.

Working Capital Drives Cash Volatility

Based on EDBL's reported figures, working capital changes swung from a $17.4M outflow in 2025Q4 to a $10.3M inflow in 2025Q3, indicating that receivables, inventory, and payables timing dominates quarterly cash results.

The magnitude of quarterly working capital movements relative to net income suggests that collection timing and wholesaler inventory stocking may be creating substantial noise in reported cash flow. Large swings of this size imply that a meaningful share of quarterly operating cash flow may reverse in subsequent periods. Analysts should examine receivables aging and inventory levels to determine whether recent inflows reflect genuine collections or temporary balance sheet movements.

Cumulative Cash Lags Reported Profits

Across the ten reported quarters, cumulative operating cash flow appears modestly ahead of cumulative net income, though the result depends heavily on the timing of the most recent quarter's inflow.

Summing the disclosed quarters suggests operating cash flow has broadly tracked net income over the period, but the path is uneven and dominated by a few large swings. The pattern indicates that the company's earnings history is not yet a reliable proxy for cash generation. Investors should treat the recent positive cash result as encouraging but not yet proof of durable cash earnings power.

Cash Strength May Be Temporary

The recent cash inflows may reflect working capital release and launch timing rather than recurring cash earnings, and the -5.8% TTM net margin and -18.2% ROE caution against extrapolating current results.

The strongest bear case is that the 2026Q3 operating cash inflow of $35.2M is a one-time working capital reversal following the $17.4M outflow in the prior quarter, not a new run rate. Trailing profitability remains negative, which suggests the business has not yet demonstrated that revenue growth converts to sustained cash earnings. Investors should monitor whether operating cash flow stays positive across several quarters before concluding the cash profile has structurally improved.

ETON — Frequently Asked Questions

Quick answers to the most common questions about buying ETON stock.

How much cash does Eton Pharmaceuticals, Inc. (ETON) generate from operations?

Eton Pharmaceuticals, Inc. (ETON) generated $10.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Eton Pharmaceuticals, Inc.'s free cash flow?

Eton Pharmaceuticals, Inc. (ETON) generated $10.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Eton Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Eton Pharmaceuticals, Inc. (ETON) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.